Tag: CHARCOTMARIETOOTH
Pharnext advances analysis of data from the pivotal Phase III study of PXT3003 in Charcot-Marie-Tooth disease type 1A
By Hector Chaunu Published on 02/28/2024 at 9:00 a.m. Photo credit © ChaunuPictures (Boursier.com) — Pharnext SCA,…
PHARNEXT: Pharnext announces its intention to prepare registration and marketing authorization files for PXT3003, its drug candidate in Charcot-Marie-Tooth disease type 1A – 12/19/2023 at 08:00: 00
PARIS, France, December 19, 2023 at 8:30 a.m. (CET) – Pharnext SCA (FR001400JXB0 – ALPHA) (the “Company”), an advanced clinical stage biopharmaceutical company developing new therapies for neurodegenerative diseases without…
Pharnext: offer for its drug candidate in Charcot-Marie-Tooth disease type 1A
(AOF) – Pharnext, an advanced clinical stage biopharmaceutical company developing new therapies for neurodegenerative diseases, announced that it has received a non-binding offer with a view to signing an agreement…
PHARNEXT: Pharnext receives a new offer valuing its drug candidate in Charcot-Marie-Tooth disease type 1A at more than 500 MEUR and the support of its financial partners – 10/30/2023 at 08:30
PARIS, France, October 30, 2023 at 8:30 a.m. (CET) – Pharnext SCA (FR001400JXB0 – ALPHA) (the “Company”), an advanced clinical stage biopharmaceutical company developing new therapies for neurodegenerative diseases without…
PHARNEXT: The latest results from CMTMe, a digital study evaluating the lifestyle of patients with Charcot-Marie-Tooth diseases (CMTs), will be presented at the 2023 Annual Meeting of the Peripheral Nerve Society (‘PNS’) – 14/ 06/2023 at 08:30
PARIS, France, June 14, 2023 at 8:30 a.m. (CET) – Pharnext SA (FR001400GUN7 – ALPHA) (the “Company”), a late-stage biopharmaceutical company developing new therapies for neurodegenerative diseases with no satisfactory…
Pharnext supports and participates in the First European Conference of Charcot-Marie-Tooth disease specialists
By Claude Leguilloux Published on 06/08/2023 at 08:43 Photo credit © ChaunuPictures (Boursier.com) — Pharnext SA, a late-stage…
PHARNEXT: Data on the impact of fatigue in patients with Charcot-Marie-Tooth disease, from the CMT and Me digital study, will be presented during a webinar organized with CMT UK – 03/23/ 2023 at 08:30
PARIS, France, March 23, 2023 at 8:30 a.m. (CET) – Pharnext SCA (FR001400BV89 – ALPHA) (the “Company”), a late-stage biopharmaceutical company developing new therapies for neurodegenerative diseases with no satisfactory…
Pharnext signs a financing agreement with Néovacs for a net amount of 20.7 million euros allowing the continuation of the development of PXT3003 in Charcot-Marie-Tooth disease type 1A – 10/03/2022 at 18:00
• At the end of this financing program, carried out via the issue in several tranches of simple bonds for a total nominal amount of approximately 21 million euros (i.e.…
Pharnext announces the inclusion of the first patient in the open label extension of the pivotal Phase III study of PXT3003 in Charcot-Marie-Tooth disease type 1A, the PREMIER trial – 09/12/2022 at 08: 30
PARIS, France, September 12, 2022 at 8:30 a.m. (CET) – Pharnext SA (FR0011191287 – ALPHA) (“the Company”), an advanced clinical-stage biopharmaceutical company developing new therapies for neurodegenerative diseases with no…
Pharnext Announces Enrollment of the First Patient in the Open-Label Extension of the Pivotal Phase III Study of PXT3003 in Charcot-Marie-Tooth Disease Type 1A, the PREMIER Trial
Pharnext Announces Enrollment of the First Patient in the Open-Label Extension of the Pivotal Phase III Study of PXT3003 in Charcot-Marie-Tooth Disease Type 1A, the PREMIER Trial PARIS, France, September…
NEOVACS: NEOVACS PLANS TO INVEST IN PHARNEXT TO FUND PIVOT PHASE III CLINICAL STUDY OF PXT3003 IN CHARCOT-MARIE-TOOTH DISEASE TYPE 1A – 08/08/2022 at 08:00
Paris, August 8, 2022 – 8 a.m. CET – Neovacs (Euronext Growth Paris: ALNEV) announces that it has entered into negotiations with the company Pharnext (Euronext Growth Paris: ALPHA) in…